Domestic drug makers rush to develop amlodipine preparations

Korea's pharmaceutical firms are scrambling to develop the first-generic versions of Pfizer Korea's Norvasc valued at 150 billion won last year and the foreign-invested pharmaceutical firm is expected to face an uphill battle in Korea from next year due to expected fierce competition from domestic makers, industry sources recently.

Currently, the product patent of Amlodipine besylate...